Skip to content

AVANIR PHARMACEUTICALS, INC.: 10-Q filed 2014-05-07

What AVANIR PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-05-07 (fiscal Q2 2014): 32 published measures, 82 facts as tagged in accession 0001193125-14-187139.

This filing

Form
10-Q (quarterly report)
Filed
2014-05-07
Fiscal period
fiscal Q2 2014
Accession
0001193125-14-187139 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AVANIR PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-3183,609,261USD
At 2013-09-3076,079,007USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-3155,956,088USD
At 2013-09-3057,607,453USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-3127,653,173USD
At 2013-09-3018,471,554USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-03-3153,888,058USD
At 2013-09-3055,259,073USD
At 2013-03-3167,859,426USD
At 2012-09-3069,778,406USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-12,677,756USD90
2013-10-01 to 2014-03-31-23,624,293USD182
2013-01-01 to 2013-03-31-16,526,701USD90
2012-10-01 to 2013-03-31-28,602,783USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-10-01 to 2014-03-31-25,511,536USD182
2012-10-01 to 2013-03-31-22,296,056USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-10-01 to 2014-03-312,223,720USD182
2012-10-01 to 2013-03-31279,984USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-10-01 to 2014-03-3126,715,930USD182
2012-10-01 to 2013-03-3120,660,573USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-10-01 to 2014-03-31-2,575,409USD182
2012-10-01 to 2013-03-31-283,497USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-03-31-524,160,182USD
At 2013-09-30-500,535,889USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-03-313,153,568USD
At 2013-09-301,592,791USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-03-311,993,759USD90
2013-10-01 to 2014-03-313,381,876USD182
2013-01-01 to 2013-03-311,789,302USD90
2012-10-01 to 2013-03-313,196,310USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-11,775,178USD90
2013-10-01 to 2014-03-31-21,771,784USD182
2013-01-01 to 2013-03-31-15,482,718USD90
2012-10-01 to 2013-03-31-26,518,886USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-03-3177,692,830USD
At 2013-09-3071,843,640USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-01 to 2014-03-31898,316USD90
2013-10-01 to 2014-03-311,853,211USD182
2013-01-01 to 2013-03-311,059,245USD90
2012-10-01 to 2013-03-312,118,490USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-3138,240,577USD
At 2013-09-3034,792,215USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-03-319,894,886USD
At 2013-09-305,876,425USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-03-3117,215,906USD
At 2013-09-3012,525,992USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-01-01 to 2014-03-3138,721,882USD90
2013-10-01 to 2014-03-3175,464,907USD182
2013-01-01 to 2013-03-3132,916,906USD90
2012-10-01 to 2013-03-3160,473,346USD182

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2014-03-31640,853USD
At 2013-09-30710,179USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-03-319,892,256USD90
2013-10-01 to 2014-03-3119,417,576USD182
2013-01-01 to 2013-03-318,874,298USD90
2012-10-01 to 2013-03-3115,522,389USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-03-31159,825,804shares
At 2013-09-30152,063,621shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-03-31686,154USD
At 2013-09-30554,452USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-03-312,019,000USD
At 2013-09-301,393,075USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-03-3110,692,697USD
At 2013-09-3011,908,570USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-318,555,381USD90
2013-10-01 to 2014-03-3117,005,271USD182
2013-01-01 to 2013-03-316,978,684USD90
2012-10-01 to 2013-03-3113,517,087USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-10-01 to 2014-03-31509,229USD182
2012-10-01 to 2013-03-31408,261USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-9,249USD90
2013-10-01 to 2014-03-31-8,837USD182
2013-01-01 to 2013-03-31197USD90
2012-10-01 to 2013-03-31197USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-10-01 to 2014-03-3129,304,970USD182
2012-10-01 to 2013-03-3119,101,955USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2013-10-01 to 2014-03-314,689,914USD182
2012-10-01 to 2013-03-312,448,016USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2013-10-01 to 2014-03-31-80,383USD182
2012-10-01 to 2013-03-3113,496USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-10-01 to 2014-03-314,048,278USD182
2012-10-01 to 2013-03-314,624,085USD182

Inspect the source

Entity
AVANIR PHARMACEUTICALS, INC. / CIK 0000858803
Captured
SEC response SHA-256
4bc74dbc3fac389feeddad4cf6bebf9b8d6610bb15c26be4da3356b3170f82c7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000858803.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))